Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma
T. G. Murray, D. B. Roth, J. M. O'Brien, W. Feuer, N. Cicciarelli, A. M. Markoe, E. Hernandez, B. J. Smith and J. J. Windle
Department of Ophthalmology, University of Miami, Fla, USA.
BACKGROUND: Combined modality therapy in the treatment of retinoblastoma
may decrease treatment-related morbidity and second tumor-associated
mortality, while maintaining excellent tumor control rates. OBJECTIVE: To
evaluate tumor control and potential synergy between intravitreally
delivered carboplatin and external beam radiation therapy (EBRT), using a
transgenic murine model of spontaneous heritable retinoblastoma. METHODS:
Sixty-six mouse eyes from 4-week-old transgenic mice positive for the
simian virus 40 large T antigen were evaluated. Thirty-three mice were
treated with 5 intravitreal injections of carboplatin (ranging from 0.1-4.0
micrograms) combined with concurrent bilateral EBRT (ranging from 10-30 Gy)
delivered in twice daily 5-Gy fractions. All eyes were followed up for
treatment complications. Twelve weeks following final treatment, all eyes
were enucleated, serial histologic sections obtained, and the eyes examined
for the presence of retinoblastoma. RESULTS: No eye treated with 0.1
microgram of carboplatin and EBRT exhibited tumor control. Three (75%) of 4
mice receiving 1.0 microgram of carboplatin combined with 10-Gy EBRT had
complete tumor control. Four (100%) of 4 mice receiving 1.0 microgram of
carboplatin combined with 30-Gy EBRT had complete tumor control. Nine
(100%) of 9 mice receiving 4.0 micrograms of carboplatin in combination
with EBRT had complete tumor control. The chemotherapeutic enhancement
ratio ranged from 1.07 to 3.24. CONCLUSIONS: Combined administration of
intravitreal carboplatin and EBRT enhances local tumor control in murine
retinoblastoma. Combining these treatment modalities may allow tumor
control in selected patients with retinoblastoma while decreasing
treatment-related morbidity and the mutagenic risks associated with
radiation and systemic chemotherapy.
Mechanism of Retinoblastoma Tumor Cell Death after Focal Chemotherapy, Radiation, and Vascular Targeting Therapy in a Mouse Model
Jockovich et al.
IOVS 2007;48:5371-5376.
ABSTRACT
| FULL TEXT
Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of Retinoblastoma
Suarez et al.
IOVS 2007;48:3437-3440.
ABSTRACT
| FULL TEXT
Iontophoretic delivery of Carboplatin in a murine model of retinoblastoma.
Hayden et al.
IOVS 2006;47:3717-3721.
ABSTRACT
| FULL TEXT
Pharmacokinetics of Systemic Versus Focal Carboplatin Chemotherapy in the Rabbit Eye: Possible Implication in the Treatment of Retinoblastoma
Hayden et al.
IOVS 2004;45:3644-3649.
ABSTRACT
| FULL TEXT
External Beam Radiation "Salvage" Therapy in Transgenic Murine Retinoblastoma
Sobrin et al.
Arch Ophthalmol 2004;122:251-257.
ABSTRACT
| FULL TEXT
Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy
Sussman et al.
Arch Ophthalmol 2003;121:979-984.
ABSTRACT
| FULL TEXT
Hyperfractionated External Beam Radiation Therapy in the Treatment of Murine Transgenic Retinoblastoma
Hayden et al.
Arch Ophthalmol 2002;120:353-359.
ABSTRACT
| FULL TEXT
Subconjunctival Carboplatin in Retinoblastoma: Impact of Tumor Burden and Dose Schedule
Hayden et al.
Arch Ophthalmol 2000;118:1549-1554.
ABSTRACT
| FULL TEXT
External Beam Radiotherapy in Retinoblastoma: Tumor Control and Comparison of 2 Techniques
Scott et al.
Arch Ophthalmol 1999;117:766-770.
ABSTRACT
| FULL TEXT
Clinicopathologic Features of Retinoblastoma After Primary Chemoreduction
Bechrakis et al.
Arch Ophthalmol 1998;116:887-893.
ABSTRACT
| FULL TEXT
